TG Therapeutics (NASDAQ:TGTX) PT Raised to $49.00 at HC Wainwright

TG Therapeutics (NASDAQ:TGTX) had its price target boosted by research analysts at HC Wainwright from $45.00 to $49.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 202.66% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. LADENBURG THALM/SH SH increased their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Finally, B. Riley increased their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.83.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded down $0.23 on Thursday, reaching $16.19. 4,804,428 shares of the company were exchanged, compared to its average volume of 3,980,529. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of 70.39 and a beta of 2.33. The company has a 50-day moving average of $15.25 and a 200-day moving average of $14.41.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The company had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. During the same period last year, the company earned ($0.28) earnings per share. The business’s revenue for the quarter was up 713.5% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics will post -0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Pingora Partners LLC purchased a new position in shares of TG Therapeutics during the 4th quarter worth about $27,000. PNC Financial Services Group Inc. raised its holdings in TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the period. NBC Securities Inc. purchased a new position in TG Therapeutics in the third quarter valued at approximately $58,000. Anchor Investment Management LLC purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $80,000. Finally, REDW Wealth LLC acquired a new stake in TG Therapeutics in the third quarter valued at approximately $84,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.